Safety of tocilizumab in COVID‐19 pregnant women and their newborn: A retrospective study

Tocilizumab is an IL‐6 receptor inhibitor agent which has been proposed as a candidate to stop the inflammatory phase of infection by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). However, safety data of tocilizumab in pregnant women and their newborn are scarce. We aimed to describe maternal and neonatal safety outcomes associated with tocilizumab treatment in pregnant women with severe COVID‐19.

[1]  Christopher M. Horvat,et al.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 , 2021, medRxiv.

[2]  G. Criner,et al.  Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia , 2020, The New England journal of medicine.

[3]  E. Olsen,et al.  Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[4]  G. Mutlu,et al.  IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections , 2020, Frontiers in Medicine.

[5]  J. Parr.  Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia. , 2020, JAMA internal medicine.

[6]  R. Porcher,et al.  Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[7]  M. Massari,et al.  Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[8]  M. Massari,et al.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[9]  Xiang Chen,et al.  Characteristics of pregnant patients with COVID-19 and liver injury , 2020, Journal of Hepatology.

[10]  D. Larrey,et al.  Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same , 2020, Drug Safety.

[11]  Á. Soriano,et al.  Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection , 2020, medRxiv.

[12]  E. Carreras,et al.  Pre‐eclampsia‐like syndrome induced by severe COVID‐19: a prospective observational study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[13]  S. Antinori,et al.  Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy , 2020, European Journal of Internal Medicine.

[14]  G. Mutlu,et al.  IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections , 2020, medRxiv.

[15]  Z. Nazar,et al.  Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol , 2020, Systematic Reviews.

[16]  A. Omrani,et al.  Tocilizumab for the treatment of severe coronavirus disease 2019 , 2020, Journal of medical virology.

[17]  T. Bove,et al.  Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care , 2020, medRxiv.

[18]  M. Metra,et al.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy , 2020, Autoimmunity Reviews.

[19]  J. Qiao,et al.  Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China , 2020, The New England journal of medicine.

[20]  O. Andersson,et al.  Maternal and perinatal outcomes with COVID‐19: A systematic review of 108 pregnancies , 2020, Acta obstetricia et gynecologica Scandinavica.

[21]  J. Kwak‐Kim,et al.  Why are pregnant women susceptible to COVID-19? An immunological viewpoint , 2020, Journal of Reproductive Immunology.

[22]  D. Brennan,et al.  Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients , 2020, Transplantation direct.

[23]  S. Rasmussen,et al.  Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know , 2020, American Journal of Obstetrics and Gynecology.

[24]  H. Elgharably,et al.  Cytomegalovirus immunoglobulin G titers do not predict reactivation risk in immunocompetent hosts , 2019, Journal of medical virology.

[25]  Zhanguo Li,et al.  Pulse corticosteroids in treatment of rheumatic disease concomitant with cytomegalovirus infection , 2019, International journal of rheumatic diseases.

[26]  J. Kremer,et al.  Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis , 2017, Arthritis & rheumatology.

[27]  M. Hoeltzenbein,et al.  Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. , 2016, Seminars in arthritis and rheumatism.

[28]  Akira Ishii,et al.  Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review , 2016, Case reports in medicine.

[29]  S. Kaneko,et al.  Cytomegalovirus Reactivation Induced Acute Hepatitis and Gastric Erosions in a Patient with Rheumatoid Arthritis under Treatment with an Anti-IL-6 Receptor Antibody, Tocilizumab. , 2016, Internal medicine.

[30]  C. Henquell,et al.  Monitoring of Epstein-Barr virus (EBV)/cytomegalovirus (CMV)/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. , 2016, Joint, bone, spine : revue du rhumatisme.

[31]  M. Mochizuki,et al.  Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan , 2016, Modern rheumatology.

[32]  Isabel Folatre,et al.  [Comparison of two methods to assess causality of adverse drug reactions]. , 2015, Revista medica de Chile.

[33]  M. Doherty.  Algorithms for assessing the probability of an Adverse Drug Reaction , 2009 .

[34]  T. Ng,et al.  Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome , 2004, American Journal of Obstetrics and Gynecology.

[35]  W. Britt,et al.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity , 2001, The New England journal of medicine.